In conclusion, the present study demonstrates that impairment of FOXM1 expression in MSC isolated from de novo and therapy-related myeloid neoplasms may underlie their defective capacity to support normal hematopoiesis. The gene discussed is FOXM1; the disease is myeloid neoplasm.